Abstract
Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to reduce the risk of colorectal cancer (CRC). They are also known to induce the regression of colorectal adenomas, which are precursors to CRC. Despite these evidences, the exact mechanism by which NSAIDs exerts its anti-oncogenic effect is not completely understood. Using a focus formation assay, here we show that sulindac sulfide, a NSAID, specifically inhibits cell transformation mediated by oncogenic Ha-Ras, but not by other established oncogene products such as v-Src, Gα12, and Gα13. Our results suggest that the ability of sulindac sulfide to suppress transformation is confined to specific oncogenic pathways. Further studies of the sulindac-resistant oncogenic pathways may lead to identification of novel therapeutic agents that are effective in the prevention or treatment of CRC.
| Original language | English |
|---|---|
| Pages (from-to) | 89-94 |
| Number of pages | 6 |
| Journal | Cancer Letters |
| Volume | 175 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 10 2002 |
Keywords
- Chemoprevention
- Focus formation assay
- Gα12
- Gα13
- Ha-Ras
- Non-steroidal anti-inflammatory drugs
- Oncogene
- Transformation
- v-Src
Fingerprint
Dive into the research topics of 'Inhibition of cell transformation by sulindac sulfide is confined to specific oncogenic pathways'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver